论文部分内容阅读
环孢菌素 A(CS)系瑞士山道士公司的研究人员于1970年从真菌中分离的;它是第一种能选择性抑制某些免疫组成细胞激活作用的物质。这一研究成果使移植外科,特别是心脏和肾移植领域迈出了关键性的一步。CS发展成为一种药物——Sandimmun,并首先在瑞士注册,共花费了12年时间。有一大批化学家、生物学家、药理学家、药剂师、毒物学家及临床医师参与和仍在继续此项研究。CS 的问世标志着骨髓移植和器官移植在免疫治疗方面的重大进展。作用范围CS 作为专供器官移植使用的药物,至今虽然已在20多个国家注册,但作为对自体免疫病的一种新药的潜力,现正在评价中。同许多有效药物一样,CS 难免也有副作用。
Cyclosporin A (CS) was isolated from fungi in 1970 by researchers from Mount Bacchus; it is the first substance to selectively inhibit cellular activation of certain immune components. This research represents a crucial step in the field of transplant surgery, especially heart and kidney transplantation. CS developed into a drug, Sandimmun, and was first registered in Switzerland for a total of 12 years. A large number of chemists, biologists, pharmacologists, pharmacists, toxicologists and clinicians are involved in and continue the study. The advent of CS marks a major advance in immunotherapy for bone marrow transplantation and organ transplantation. Scope of action CS, a drug devoted exclusively to organ transplantation, has so far been evaluated as a new drug for autoimmune diseases, although registered in more than 20 countries. Like many active drugs, CS inevitably has side effects.